JANONE CONFIRMS NAME CHANGE TO ALT5 SIGMA CORPORATION AND NEW TICKER SYMBOL FOR ALTS

LAS VEGAS, July 13, 2024 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a multi-disciplinary organization focused on fintech and healthcare, today confirmed that, effective at the market open on Monday, July 15, 2024, the Company’s new name will be “ALT5 Sigma Corporation” and the ticker symbol for its Nasdaq common stock will change to “ALTS.” This will replace the Company’s current ticker symbol of “JAN.” Additionally, the Company’s website address will change from “janone.com” to “alt5sigma.com.”

The company’s name, ticker symbol and website address change is in line with the company’s realignment to focus on its recently acquired fintech ALT5 Sigma as its primary revenue growth driver.

This realignment and the changes to the corporate name and ticker symbol were previously announced on July 10, 2024. No action is required by the Company’s stockholders regarding the change in ticker symbol. The Company’s CUSIP number and transfer agent will remain unchanged.

Highlighting the changes confirmed today, Tony Isaac, the company’s CEO, noted, “We are pleased to complete the changes to our name and ticker symbol as the first steps in our previously announced diversification into the fintech sector, while keeping the trajectory of our biotech business on track, all for the benefit of our shareholders.”

About JanOne/ALT5 Sigma

The Company is a unique multidisciplinary organization listed on Nasdaq, focused on healthcare and fintech. The Company is a component of the Russell Microcap Index, effective June 28, 2024.

Through its fintech businesses, the Company provides next-generation blockchain-based technologies to enable a migration to a new global financial paradigm for trading, clearing, settlement, payment and custody of digital instruments. Through its fintech subsidiaries, the Company offers two main platforms to its customers: “ALT5 Pay” and “ALT5 Prime”. The subsidiaries processed over $1.2 billion in cryptocurrency transactions in 2023.

ALT5 Pay is a cryptocurrency payment gateway that allows registered and approved global merchants to accept and make cryptocurrency payments or integrate the ALT5 Pay payment platform into their application or operations using the WooCommerce plugin and/or ALT5 Pay checkout widgets and APIs. Merchants have the option to automatically convert to fiat currency or receive payment in digital assets.

ALT5 Prime is an over-the-counter electronic trading platform that allows registered and approved clients to buy and sell digital assets. Clients can buy digital assets with fiat and, similarly, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based mobile application called “ALT5 Pro” that can be downloaded from the Apple App Store, Google Play, via ALT5 Prime’s FIX API, as well as via Broadridge Financial Solutions’ NYFIX Gateway for approved clients.

Through its biotechnology businesses, the Company is developing innovative and actionable solutions to end the opioid crisis. The Company is committed to funding innovation, technology and education resources to find a key solution to the nation’s opioid epidemic, which is one of the deadliest and most widespread in the nation’s history. Its drugs in the clinical trial pipeline have shown promise for their innovative targeting of the causes of pain as a strategic option for physicians averse to exposing patients to addictive opioids.

Forward-Looking Statements

This press release contains statements that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the profitability and prospective growth of ALT5’s platforms and business, which may include, but are not limited to, international currency risks, third-party or customer credit risks, liability claims arising from ALT5’s services, and technological challenges to future growth or expansion. This press release also contains statements and links regarding the risks that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the start of clinical trials, that the FDA will permit approval via a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately discontinue the market for PAD, and other statements, including words such as “continue,” “expect,” “intend,” “will,” “hope,” “should,” “would,” “could,” “potential” and other similar expressions. Such statements reflect the Company’s current view of future events, are subject to risks and uncertainties, and are necessarily based on a number of estimates and assumptions that, while the Company believes are reasonable, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies.

Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors may include, among others, those detailed in the Company’s periodic reports filed with the Securities and Exchange Commission (the “SEC”). If one or more of these risks or uncertainties materialize, or if the assumptions set forth in the section entitled “Risk Factors” in the Company’s filings with the SEC that underlie such forward-looking statements prove incorrect, actual results could vary materially from those described herein. Such forward-looking statements are made as of the date of this press release, and the Company does not intend and undertakes no obligation to update such forward-looking statements except as required by law. The Company cannot assure you that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and, accordingly, they are cautioned not to place undue reliance on such statements because of the inherent uncertainty therein.

Media Contact Investor Relations
[email protected]
Toll-free number 800-400-2247

Logo – Italian: https://mma.prnewswire.com/media/973662/JanOne_With_4C_TM_Logo.jpg

Source